Completed PHASE1 INTERVENTIONAL 2-arm NCT02280434

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CBP-307 Following Oral Single and Multiple Escalating Dose Administration

Sponsor: Connect Biopharm LLC

Conditions Autoimmune Diseases

Interventions CBP-307 Placebo

Updated 6 times since 2017 Last updated: Nov 1, 2016 Started: Nov 30, 2014 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02280434, this PHASE1 trial focuses on Autoimmune Diseases and remains completed. Sponsored by Connect Biopharm LLC, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Apr 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Connect Biopharm LLC
Nucleus Network Ltd
Tigermed Consulting Co., Ltd

Data source: Connect Biopharm LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia